Trial | NCT00500409  Report issue

Title

Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis
Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis. A Randomized Controlled Open-label Multicentre Study in India

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    82
OSTEOFORM, containing recombinant (rhPTH [1-34]), enhances bone mineral density and reduces risk for vertebral fracture. This study evaluates the safety and efficacy of OSTEOFORM in the treatment of osteoporosis in post-menopausal women.
207 post-menopausal women were enrolled for screening at 6 centres, and supplemented with daily 1000 mg elemental calcium and 500 IU of vitamin D for 45 days. 82 eligible women with osteoporosis were randomly received daily either calcium and vitamin D alone (control group) or Osteoform 20 µg subcutaneously with calcium and vitamin D (drug group) for 12 months. End points such as percentage of increase in bone mineral density and, changes in bone biomarkers (serum osteocalcin, bone specific alkaline phosphatase, and urinary DPD) were evaluated at baseline, and 6 and 12 months after supplementation. Besides, safety parameters and adverse events were monitored through out the study period.
Study Started
Dec 31
2005
Primary Completion
Dec 31
2006
Study Completion
Jul 31
2007
Last Update
Dec 16
2014
Estimate

Drug Osteoform

Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days

Drug SHELCAL

Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days

  • Other names: Calcium and vitamin D

Drug Group Experimental

Osteoform

Control group Active Comparator

SHELCAL

Criteria 

Inclusion Criteria:

Postmenopausal women with osteoporosis (Lumbar spine or femoral neck BMD or total hip T-score less than or equal to-2.5)

Exclusion Criteria:

Women with vertebral (L1-L4) abnormalities that preclude accurate measurement by DEXA.
Women on medications that are known to affect bone for more than 7 days in the past 6 months.
Currently taking systemic prednisone, inhaled steroids, anticoagulants, anticonvulsants.
History of rhPTH use or known hypersensitivity to study drug.
Vitamin D3 deficiency (Vitamin D3 < 20 ng/ml).
Abnormal thyroid function.
History of kidney disease.
Any history of hypercalciuria, hypercalcemia or hyperparathyroidism.
History of active or treated tuberculosis or significant liver disease or gastrointestinal disease or cancer.
No Results Posted